Perioperative management of coagulation in nontraumatic intracerebral hemorrhage

Anesthesiology

Volumn 119, Issue 1, 2013, Pages 218-224

  Degos, Vincent ^a,b   Westbroek, Erick M ^a   Lawton, Michael T ^a   Hemphill III, J Claude ^c   Del Zoppo, Gregory J ^d   Young, William L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; FIBRINOGEN RECEPTOR; HEPARIN; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONFORMATIONAL TRANSITION; CRANIOTOMY; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; FIBRINOLYTIC AGENTS; HEMOSTATICS; HUMANS; INTRACRANIAL HEMORRHAGES; INTRAOPERATIVE PERIOD; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; VITAMIN K;

EID: 84883213668     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318297c18a     Document Type: Note

References (44)

1. Flaherty ML: Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010; 30:565-72
2. Morgenstern LB, Hemphill JC III, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ; American Heart Association Stroke Council and Council on Cardiovascular Nursing: Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2010; 41:2108-29
3. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP: The increasing incidence of anticoagulant- associated intracerebral hemorrhage. Neurology 2007; 68:116-21
4. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians: New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 suppl):e120S-51S
5. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: A guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001-23
6. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164:880-4
7. Brouwers HB, Goldstein JN: Therapeutic strategies in acute intracerebral hemorrhage. Neurotherapeutics 2012; 9:87-98
8. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Karttunen V, Karajamaki A, Hillbom M: Improved survival of patients with warfarin-associated intracerebral haemorrhage: A retrospective longitudinal population-based study. Int J Stroke 2012; [Epub ahead of print]
9. Zazulia AR, Diringer MN, Derdeyn CP, Powers WJ: Progression of mass effect after intracerebral hemorrhage. Stroke 1999; 30:1167-73
10. Hemphill JC III, Bonovich DC, Besmertis L, Manley GT, Johnston SC: The ICH score: A simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32:891-7
11. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1-5
12. Adams RL, Bird RJ: Review article: Coagulation cascade and therapeutics update: Relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants. Nephrology (Carlton) 2009; 14:462-70
13. Roberts HR, Monroe DM, Escobar MA: Current concepts of hemostasis: Implications for therapy. Anesthesiolog y 2004; 100:722-30
14. del Zoppo GJ, Yu JQ, Copeland BR, Thomas WS, Schneiderman J, Morrissey JH: Tissue factor localization in non-human primate cerebral tissue. Thromb Haemost 1992; 68:642-7
15. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ: Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45:12020-8
16. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, Watanabe T, Kimura T, Sasaki T: Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: Possible role in pathogenesis of cerebral vasospasm. Stroke 2001; 32:2913-9
17. Hillered L, Valtysson J, Enblad P, Persson L: Interstitial glycerol as a marker for membrane phospholipid degradation in the acutely injured human brain. J Neurol Neurosurg Psychiatry 1998; 64:486-91
18. Hirashima Y, Nakamura S, Endo S, Kuwayama N, Naruse Y, Takaku A: Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997; 22:1249-55
19. Cohen MJ, Brohi K, Ganter MT, Manley GT, Mackersie RC, Pittet JF: Early coagulopathy after traumatic brain injury: The role of hypoperfusion and the protein C pathway. J Trauma 2007; 63:1254-61; discussion 1261-2
20. Kidwell CS, Burgess R, Menon R, Warach S, Latour LL: Hyperacute injury marker (HARM) in primary hemorrhage: A distinct form of CNS barrier disruption. Neurology 2011; 77:1725-8
21. Wada R, Aviv RI, Fox AJ, Sahlas DJ, Gladstone DJ, Tomlinson G, Symons SP: CT angiography "spot sign" predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38:1257-62
22. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, Molina CA, Blas YS, Dzialowski I, Kobayashi A, Boulanger JM, Lum C, Gubitz G, Padma V, Roy J, Kase CS, Kosior J, Bhatia R, Tymchuk S, Subramaniam S, Gladstone DJ, Hill MD, Aviv RI; PREDICT/Sunnybrook ICH CTA Study Group: Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): A prospective observational study. Lancet Neurol 2012; 11:307-14
23. He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. JAMA 1998; 280:1930-5
24. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S: Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke 2012; 43:1511-7
25. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L: Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32:2933-44
26. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 suppl):160-98S
27. Gerlach R, Scheuer T, Beck J, Woszczyk A, Seifert V, Raabe A: Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: Results of a prospective study. Neurosurgery 2003; 53:1028-34; discussion 1034-5
28. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ: Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110:453-60
29. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-92
30. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19
31. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J: Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87(suppl 1):S141-5
32. Schellinger PD, Fiebach JB, Mohr A, Ringleb PA, Jansen O, Hacke W: Thrombolytic therapy for ischemic stroke- A review. Part I-Intravenous thrombolysis. Crit Care Med 2001; 29:1812-8
33. Larrue V, von Kummer R R, Müller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32:438-41
34. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M: PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29:4-11
35. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-85
36. Levi M, Levy JH, Andersen HF, Truloff D: Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-800
37. Samama MM, Guinet C, Le Flem L: Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 2012; 130(suppl 1):S88-9
38. Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC: Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: A pilot study. Neurocrit Care 2004; 1:47-51
39. Sorimachi T, Fujii Y, Morita K, Tanaka R: Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005; 57:837-44
40. Neal M, Crowther M, Douketis J, Verhovsek M, Stidley C, Garcia D: Reversal of vitamin K antagonist-associated coagulopathy: A survey of current practice. Thromb Res 2008; 122:864-6
41. Boulis NM, Bobek MP, Schmaier A, Hoff JT: Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45:1113-8; discussion 1118-9
42. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE: Rapid warfarin reversal: A 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg 2012; 116: 491-7
43. Mayer SA, Davis SM, Skolnick BE, Brun NC, Begtrup K, Broderick JP, Diringer MN, Steiner T; FAST Trial Investigators: Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII? Stroke 2009; 40:833-40
44. Effect of tranexamic acid in traumatic brain injury: A nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343:d3795